Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors
24 November 2020 - 11:00PM
Business Wire
Mr. Ignelzi brings strong financial and
operational expertise to the board and will serve as chairman of
the Audit Committee
Vedanta Biosciences, a leading clinical-stage company developing
a new category of therapies for immune-mediated diseases based on
rationally-defined consortia of human microbiome-derived bacteria,
today announced the appointment of Troy Ignelzi as an independent
member of its Board of Directors. Mr. Ignelzi has more than 25
years of experience supporting life science companies in finance,
business development and operations, and has helped oversee their
evolutions from privately held, clinical-stage companies to
publicly traded biopharmaceutical companies preparing for
commercial launches.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201124005333/en/
Vedanta Biosciences announced the
appointment of Troy Ignelzi as an independent member of its Board
of Directors. Mr. Ignelzi has more than 25 years of experience
supporting life science companies in finance, business development
and operations, and has helped oversee their evolutions from
privately held, clinical-stage companies to publicly traded
biopharmaceutical companies preparing for commercial launches.
(Photo: Business Wire)
“We’re excited to welcome Troy to the Vedanta board,” said
Bernat Olle, Ph.D., co-founder and chief executive officer of
Vedanta Biosciences. “Troy has a wealth of expertise in the biotech
industry that can help guide our financial strategy as we move to
our next phase of development.”
Mr. Ignelzi has played a key role in seven IPOs, and currently
serves as the chief financial officer of Karuna Therapeutics. He
joined Karuna in March 2019, coming from scPharmaceuticals, where
he was also in the role of chief financial officer, overseeing its
transformation to a company preparing for commercial launch. Prior
to scPharmaceuticals, Mr. Ignelzi was a senior executive at
Juventas Therapeutics, Esperion Therapeutics and Insys
Therapeutics, helping raise public and private capital, expand
development pipelines through licensing and acquisition and
advancing critical therapies, several of which are currently
approved by the U.S. Food and Drug Administration. Mr. Ignelzi
holds a B.A. in accounting from Ferris State University.
“This is an exciting time for Vedanta and for the microbiome
field,” said Mr. Ignelzi. “In this position, I look forward to
helping the Vedanta team advance defined bacterial consortia as a
new drug modality.”
About Vedanta Biosciences Vedanta Biosciences is leading
the development of a potential new category of oral therapies based
on rationally defined consortia of bacteria derived from the human
microbiome. The company’s clinical-stage pipeline includes product
candidates being evaluated for the treatment of high-risk C.
difficile infection, inflammatory bowel diseases, advanced or
metastatic cancers, and food allergy. These investigational
therapies are grounded in pioneering research – published in
leading journals including Science, Nature, and Cell – to identify
beneficial bacteria that live symbiotically within the healthy
human gut, fight pathogens and induce a range of potent immune
responses. Vedanta Biosciences controls a foundational portfolio of
more than 40 patents and has built what is believed to be the
world’s biggest library of bacteria derived from the human
microbiome. Proprietary capabilities include deep expertise in
consortium design, vast datasets from human interventional studies
and cGMP-compliant manufacturing of oral live biotherapeutics
containing pure, clonally derived bacterial consortia in powdered
form. Vedanta Biosciences was founded by PureTech Health (LSE:PRTC,
Nasdaq:PRTC) and a global team of scientific co-founders who
pioneered Vedanta’s modern understanding of the cross-talk between
the microbiome and the immune system.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201124005333/en/
Investors and Media Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024